Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS trial_result · 2016-03-04

Clinical Trial Update: Study of MK-8242 Alone and in Combination With Cytarabine in Participants With Acute Myelogenous Leukemia (P07649) [Phase 1]

View source ↗

Summary

Phase 1 trial of MK-8242 alone and with cytarabine in adults with acute myeloid leukemia (AML) was terminated; results posted in 2016.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • CYTARABINE (CYTARABINE)
  • MK-8242

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Acute Myelogenous Leukemia (AML) | Phase 1 | Status: TERMINATED | Results posted: 2016-03-04